cerebral spinal fluid drug
Evidence from:
primary |
all sources
No related entities found.
Mentioned in (9)
Papers in which this entity is mentioned.
- Nanopore-based cell-free DNA fragmentation and methylation profiles from the cerebral spinal fluid of patients with lung cancer brain metastases. (2025)
- Rapid brain tumor classification from sparse epigenomic data. (2025)
- Reduction of APOE accounts for neurobehavioral deficits in fetal alcohol spectrum disorders. (2024)
- Combined low-pass whole genome and targeted sequencing in liquid biopsies for pediatric solid tumors. (2023)
- Cell-free DNA technologies for the analysis of brain cancer. (2022)
- Application of third-generation sequencing in cancer research. (2021)
- Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. (2015)
- Handling changes in MRI acquisition parameters in modeling whole brain lesion volume and atrophy data in multiple sclerosis subjects: Comparison of linear mixed-effect models. (2015)
- Focus on: magnetic resonance-based studies of fetal alcohol spectrum disorders in animal models. (2011)
Merged raw entities (3)
All extracted name/type variants the normalize job merged into this entity. Use this to spot wrong merges, or aliases that should be split off.
| Raw name | Type | Papers | Mentions |
|---|---|---|---|
| csf | drug | 34 | 82 |
| cerebral spinal fluid | anatomy | 12 | 13 |
| cerebral spinal fluid | drug | 11 | 14 |